"What" Series

What is GBS? And what causes GBS?

25 December 2023
2 min read

Guillain-Barré syndrome (GBS) is a rare disorder in which a persons own immune system damages the nerve cells, causing muscle weakness and sometimes paralysis. GBS can cause symptoms that last for a few weeks or several months. Most people recover fully from GBS, but some people have permanent nerve damage. In rare cases, people have died of GBS, usually from difficulty with breathing. In the United States, for example, an estimated 3,000 to 6,000 people develop GBS each year on average, whether or not they received a vaccination. This is about 1 to 2 cases of GBS per 100,000 people.

Scientists do not fully understand what causes GBS, but it is believed that stimulation of the bodys immune system may play a role in its development. Heres what scientists know for sure: About two-thirds of people who develop GBS symptoms do so several days or weeks after they have been sick with a diarrhea or respiratory illness. Infection with the bacterium Campylobacter jejuni is one of the most common risk factors for GBS. People can also develop GBS after having the flu or other infections (such as cytomegalovirus and Epstein Barr virus). On very rare occasions, they may develop GBS in the days or weeks following receiving a vaccination.

What are the types of protein amidation modifications and their role in regulation of protein biological activity?
"What" Series
2 min read
What are the types of protein amidation modifications and their role in regulation of protein biological activity?
25 December 2023
Protein amidation is the process through which a carboxyl group is converted into an amide group.
Read →
Agomab Begins Phase I Trial of AGMB-447 in Healthy Subjects and IPF Patients
Latest Hotspot
3 min read
Agomab Begins Phase I Trial of AGMB-447 in Healthy Subjects and IPF Patients
25 December 2023
Agomab Initiates First-Stage Research Trial on AGMB-447 with Healthy Participants and Individuals Diagnosed with Idiopathic Pulmonary Fibrosis.
Read →
Understanding STAT3 Inhibitors and Methods to Keep Abreast of Their Recent Developments
Understanding STAT3 Inhibitors and Methods to Keep Abreast of Their Recent Developments
25 December 2023
The development of STAT3 inhibitors will be increasingly valued in the future, and targeting the STAT3 signaling pathway has become a promising strategy for the treatment of various cancers.
Read →
What are the advantages of Oligonucleotide drugs?
"What" Series
2 min read
What are the advantages of Oligonucleotide drugs?
25 December 2023
The emergence of oligonucleotide drugs makes it possible to actively design drug sequences to target and silence disease genes.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.